Orexo’s pain drug granted Swedish marketing authorization
It is anticipated that the product branded as ‘Abstral’ will be launched in Sweden in the third quarter of 2008 through Orexo’s joint venture with ProStrakan, the international
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).